Anagen Therapeutics is an emerging biotechnology company focused on therapies for androgen and nuclear receptor-related diseases. Specific targets for its products under development include prostate disease, cardiovascular disease, neurodegenerative disease and skin disease. We conservatively estimate that the current U.S. market for prescription-based products to treat these diseases exceeds $10 billion annually, with expected growth of 8-10% per year over the next few years.
Anagen has entered into exclusive licensing agreements with the University of Chicago for technology that forms the foundation for our product development programs. Anagen's proprietary technology base is derived from discoveries made in the laboratory of Dr. Shutsung Liao, Professor of Biochemistry and Molecular Biology at the University of Chicago and Director of the university's Tang Center for Herbal Medicine. Anagen has strong patent positions worldwide to compositions and methods for treating prostate cancer, lipid disorders, neurodegenerative disorders, and skin diseases.
Anagen is led by a veteran senior management team with a proven track record for discovery, development and commercialization of pharmaceutical products. Our headquarters are located in Chicago thus providing access to talent from the concentration of nearby healthcare companies including both large and small organizations.
